<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ENTACAPONE</span><br/>(en-ta'ca-pone)<br/><span class="topboxtradename">Comtan<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">catecholamine o-methyltransferase (comt) inhibitor</span>; <span class="classification">antiparkinsonism agent</span><br/><b>Prototype: </b>Tolcapone<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>200 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Selective inhibitor of catecholamine O-methyltransferase (COMT). COMT is responsible for metabolizing levodopa to an intermediate
         compound 3-O-methyldopa, a chemical which interferes with the availability of levodopa to the brain.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Taken with levodopa, it decreases the formation of 3-O-methyldopa, thus increasing the duration of the motor response of the
         brain to levodopa in Parkinson's disease. Indicated by diminished Parkinson's manifestations.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunct to levodopa/carbidopa to treat Parkinson's disease.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to entacapone; concurrent MAO inhibitors; pregnancy (category D), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hepatic impairment; biliary obstruction; concomitant administration with CNS depressants; lactation; drugs metabolized by
         COMT (e.g., isoproterenol, epinephrine, etc.); history of hypotension or syncope.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Parkinson's Disease</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 200 mg administered with each dose of levodopa/carbidopa up to 8 times/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give simultaneously with each levodopa/carbidopa dose.</li>
<li>Must be tapered if discontinued. Never discontinue abruptly.</li>
<li>Do not administer to patients receiving nonselective MAO inhibitors.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Back pain, fatigue, asthenia. <span class="typehead">CNS:</span> <span class="speceff-common">Dyskinesia, hyperkinesia,</span> hypokinesia, dizziness, anxiety, somnolence, agitation. <span class="typehead"> GI:</span> Taste perversion, <span class="speceff-common">nausea, diarrhea,</span> abdominal pain, constipation, vomiting, dry mouth, dyspepsia, flatulence, gastritis. <span class="typehead">Respiratory:</span> Dyspnea. <span class="typehead">Skin:</span> Increased sweating. <span class="typehead">Other:</span> <span class="speceff-common">Urine discoloration,</span> purpura. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Extreme caution must be used if administered with a nonselective <span class="classification">maoi</span>; <b>bitolterol,</b> <b>dobutamine,</b> <b>dopamine, epinephrine,</b> <b>isoetharine,</b> <b>isoproterenol,</b> <b>methyldopa,</b> <b>norepinephrine</b> may increase heart rates, possibly cause arrhythmias, excessive changes in BP. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed, 35% bioavailable. <span class="typehead">Peak:</span>  1 h. <span class="typehead"> Distribution:</span>  Highly protein bound. <span class="typehead"> Metabolism:</span>  Extensively metabolized in plasma and erythrocytes. <span class="typehead"> Elimination:</span>  Primarily excreted in feces. <span class="typehead">Half-Life:</span> 2.4 h (terminal). 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor carefully for hyperpyrexia, confusion, or emergence of Parkinson's S&amp;S during drug withdrawal.</li>
<li>Monitor for orthostatic hypotension &amp; worsening of dyskinesia or hyperkinesia.</li>
<li>Lab tests: Hgb and serum ferritin levels with prolonged therapy.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Take with levodopa/carbidopa; not effective alone.</li>
<li>Do not discontinue abruptly; gradually reduce dosage.</li>
<li>Exercise caution when rising from a sitting or lying position because faintness/dizziness can occur.</li>
<li>Exercise caution with hazardous activities until reaction to the drug is known.</li>
<li>Harmless brownish-orange discoloration of urine is possible.</li>
<li>Report unusual adverse effects (e.g., hallucinations/unexplained diarrhea).</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>